Magnasense AB Completes RADx® Tech Project Under NIH

MAR

Magnasense AB is pleased to announce the completion of Milestone 3 of the RADx® Tech project funded by the National Institutes of Health (NIH)

The report was submitted for approval and we have received official confirmation that Milestone 3 has been approved and a payment of $ 494,755 is anticipated in the coming weeks. The project has been concluded and work on Milestone 4 will no longer continue or be funded under this project.

The RADx® Tech project has been an important part of Magnasense AB’s research and development efforts, contributing to advancements in our field. We are grateful for the opportunity to collaborate with the NIH on this initiative and are excited about the continued benefits that will come from the insights gained.

A special thanks goes out to the dedicated team members who participated in the project. Their hard work, innovation, and expertise were instrumental in reaching this milestone.

This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.

Datum 2024-12-20, kl 21:10
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!